Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507922 | 0.85 | TGM2 (0.32) | AHRCMA1 | |
| Hydrochloric Acid SCHEMBL9449441 | 0.69 | MEN1 (0.31) | — | |
| SCHEMBL31223930 | 0.64 | TGM2 (0.34) | AHRCMA1 | |
| SCHEMBL20246188 | 0.63 | PNMT (0.36) | AHRPNMTASIC3 | |
| SCHEMBL16602487 | 0.61 | AHR (0.41) | AHRCMA1PNMTASIC3 | |
| SCHEMBL384362 | 0.61 | KDM4E (0.48) | AHRCMA1PNMTASIC3 | |
| SCHEMBL15373652 | 0.60 | PNMT (0.45) | AHRCMA1PNMTASIC3 | |
| SCHEMBL29414378 | 0.57 | PNMT (0.57) | AHRCMA1PNMTASIC3 | |
| SCHEMBL28904944 | 0.57 | AHR (0.37) | AHRCMA1PNMTASIC3 | |
| SCHEMBL31223925 | 0.57 | TGM2 (0.46) | AHRCMA1PNMTASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1201820-C | Compositions containing benzimidazolones and progestogens | WYETH CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| US-6794373-B2 | ADMINISTERING TO A FEMALE OF CHILD BEARING AGE OVER A PERIOD OF 28 CONSECUTIVE DAYS A FIRST PHASE OF FROM 18 TO 21 DAILY DOSAGE UNITS OF A PROGESTATIONAL AGENT, AND A SECOND PHASE OF FROM 1 TO 7 DAILY DOSAGE UNITS OF AN ANTIPROGESTIN AGENT | WYETH | 2004-09-21 | — | — | US | disclosed |
| CN-1152020-C | Benzimidazolrone and analogues, and the use as ligand of progesterone | �Ʒ� | 2004-06-02 | — | — | CN | disclosed |
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | LIGAND PHARMACEUTICALS INCORPORATED | 2002-10-17 | — | — | US | disclosed |
| US-20020115853-A1 | Benzimidazolones and analogues | WYETH | 2002-08-22 | — | — | US | disclosed |
| US-6423699-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-23 | — | — | US | disclosed |
| CN-1349411-A | Compositions containing benzimidazolones and progestogens | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| CN-1349511-A | Benzimidazolrone and analogues, and the use as ligand of progesterone | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| US-6380235-B1 | USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151531-A1 | Contraceptive methods using benzimidazolones | PGR, GNRHR, NR4A1 | AHR 92/4885CMA1 2503/4885PNMT 2394/4885 |
| US-20020115853-A1 | Benzimidazolones and analogues | PGR, NR5A1, NR3C2 | AHR 196/4885CMA1 2173/4885PNMT 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.